IL6 and Keratoconjunctivitis sicca: Notably, each component of this therapy has independent translational groundwork: QMR®-based devices have already been applied in ophthalmology (for example, improving meibomian gland function in dry eye patients with a concomitant reduction in ocular surface IL-6 levels), demonstrating the safety and efficacy of QMR® stimulation in human ocular tissues [17].